Prof. Dr. Taner Korkmaz

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

Cancers, 2026

DOI 10.3390/cancers18121979 PMID 42352512 Frei zugänglicher VolltextQuelle: OpenAlex

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

Clinical Genitourinary Cancer, 2026

DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Quelle: OpenAlex

Real-World Outcomes of Fosaprepitant-Containing Prophylaxis in Patients Receiving Highly and Moderately Emetogenic Chemotherapy: A Two-Center Retrospective Study

SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, 2026

DOI 10.14744/semb.2026.32391 PMID 42824916 Frei zugänglicher VolltextQuelle: OpenAlex

Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment

European Journal of Breast Health, 2025

DOI 10.4274/ejbh.galenos.2025.2025-10-2 PMID 41447641 Frei zugänglicher VolltextQuelle: OpenAlex

42P Concordance of CanAssist breast with Oncotype Dx and MammaPrint in patients with early stage hormone receptor positive breast cancer

ESMO Open, 2025

DOI 10.1016/j.esmoop.2025.104596 Frei zugänglicher VolltextQuelle: OpenAlex

The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

Cancers, 2025

DOI 10.3390/cancers17091592 PMID 40361516 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Cancers, 2024

DOI 10.3390/cancers16193389 PMID 39410009 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Medicine, 2024

DOI 10.1097/md.0000000000037972 PMID 38787994 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)

Oncology Letters, 2024

DOI 10.3892/ol.2024.14278 PMID 38385117 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

BMC Cancer, 2023

DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Abstract P2-11-31: FAVORABLE LOCOREGIONAL CONTROL IN CLINICALLY NODE-NEGATIVE HORMONE-RECEPTOR POSITIVE BREAST CANCER WITH LOW 21-GENE RECURRENCE SCORES: A SINGLE INSTITUTIONAL STUDY WITH 10-YEAR FOLLOW-UP

Cancer Research, 2023

DOI 10.1158/1538-7445.sabcs22-p2-11-31 1 Zitation (OpenAlex) Quelle: OpenAlex

Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

Cancers, 2023

DOI 10.3390/cancers15061667 PMID 36980554 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Journal of Cancer Research and Clinical Oncology, 2023

DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Abstract P3-02-06: Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

Cancer Research, 2023

DOI 10.1158/1538-7445.sabcs22-p3-02-06 Quelle: OpenAlex

Impact of systemic inflammatory markers in patients with ALK -positive non-small cell lung cancer treated with crizotinib

Pulmonology, 2022

DOI 10.1016/j.pulmoe.2022.11.006 PMID 36564237 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Future Oncology, 2022

DOI 10.2217/fon-2022-0083 PMID 35734870 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up

BMC Cancer, 2022

DOI 10.1186/s12885-022-10308-w PMID 36434599 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Cancer Investigation, 2021

DOI 10.1080/07357907.2021.1933011 PMID 34014777 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Journal of Thoracic Oncology, 2021

DOI 10.1016/j.jtho.2021.01.1202 Frei zugänglicher VolltextQuelle: OpenAlex

Three Cases of Breast Metastases from Lung Cancer and Systematic Review of the Literature

European Journal of Breast Health, 2020

DOI 10.4274/ejbh.galenos.2020.5703 PMID 33870122 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Lung Cancer, 2020

DOI 10.1016/j.lungcan.2020.07.022 PMID 32799090 30 Zitationen (Europe PMC) Quelle: OpenAlex

Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Cancer Research, 2020

DOI 10.1158/1538-7445.sabcs19-p5-11-19 Quelle: OpenAlex

Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e13055 Quelle: OpenAlex

P1.14-01 Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?

Journal of Thoracic Oncology, 2019

DOI 10.1016/j.jtho.2019.08.1152 Frei zugänglicher VolltextQuelle: OpenAlex

P2.01-64 Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology, 2019

DOI 10.1016/j.jtho.2019.08.1407 Frei zugänglicher VolltextQuelle: OpenAlex

Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?

Van Yüzüncü Yıl University Academic Data Management System, 2019

Quelle: OpenAlex

Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDl-1 expression in Turkish patients with gastric cancer.

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.e15538 1 Zitation (OpenAlex) Quelle: OpenAlex

P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Journal of Thoracic Oncology, 2019

DOI 10.1016/j.jtho.2019.08.1166 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

Annals of Oncology, 2019

DOI 10.1093/annonc/mdz260.069 Frei zugänglicher VolltextQuelle: OpenAlex

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Cancer Chemotherapy and Pharmacology, 2018

DOI 10.1007/s00280-018-3712-7 PMID 30377778 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

Annals of Oncology, 2018

DOI 10.1093/annonc/mdy272.315 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Journal of Thoracic Oncology, 2018

DOI 10.1016/j.jtho.2018.08.601 Frei zugänglicher VolltextQuelle: OpenAlex

Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experince from Turkey

Van Yüzüncü Yıl University Academic Data Management System, 2018

Quelle: OpenAlex

Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Bursa Uludag University - AVESIS, 2018

Quelle: OpenAlex

CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCEDSTAGE NON-SMALL CELL LUNG CANCER PATIENTS: A REAL-WORLD EXPERIENCE FROM TURKEY

Kocaeli Üniversitesi - AVESİS, 2018

Quelle: OpenAlex

Tiroid Kanserlerinde Tirozin Kinaz İnhibitör Tedavisi, Kemoterapi ve Gelecekteki Olası Tedaviler

Turkiye Klinikleri Medical Oncology - Special Topics, 2017

Quelle: OpenAlex

Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

Tumor Biology, 2016

DOI 10.1007/s13277-015-4776-1 PMID 26753955 11 Zitationen (Europe PMC) Quelle: OpenAlex

Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer

Oncology Research and Treatment, 2016

DOI 10.1159/000444272 PMID 27030981 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

İleri Evre Over Kanseri Tedavisinde Hedefe Yönelik Tedavilerin Güncel Yeri

Turkiye Klinikleri Medical Oncology - Special Topics, 2016

Quelle: OpenAlex

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Clinical Lung Cancer, 2015

DOI 10.1016/j.cllc.2015.04.006 PMID 25983005 52 Zitationen (Europe PMC) Quelle: OpenAlex

Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

Critical Reviews in Oncology/Hematology, 2015

DOI 10.1016/j.critrevonc.2015.10.006 PMID 26603345 38 Zitationen (Europe PMC) Quelle: OpenAlex

Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study

Molecular and Clinical Oncology, 2015

DOI 10.3892/mco.2015.633 PMID 26807232 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Metastasis-Induced Acute Pancreatitis Successfully Treated with Chemotherapy and Radiotherapy in a Patient with Small Cell Lung Cancer

Case Reports in Oncological Medicine, 2015

DOI 10.1155/2015/304279 PMID 26075124 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).

Journal of Clinical Oncology, 2015

DOI 10.1200/jco.2015.33.15_suppl.e11589 Quelle: OpenAlex

Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience

Asian Pacific Journal of Cancer Prevention, 2014

DOI 10.7314/apjcp.2014.15.1.117 PMID 24528011 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Three Different Chemotherapy Combinations with Concurrent Thoracic Radiation for Patients with Stage III Non-Small Cell Lung Cancer

Annals of Oncology, 2014

DOI 10.1093/annonc/mdu348.10 Frei zugänglicher VolltextQuelle: OpenAlex

Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.

Journal of Clinical Oncology, 2014

DOI 10.1200/jco.2014.32.15_suppl.7600 Quelle: OpenAlex

Primary renal carcinoid: Treatment and prognosis

Critical Reviews in Oncology/Hematology, 2013

DOI 10.1016/j.critrevonc.2013.02.003 PMID 23478151 46 Zitationen (Europe PMC) Quelle: OpenAlex

Inducible nitric oxide synthase expression in gastric adenocarcinoma: impact on lymphangiogenesis and lymphatic metastasis

Diagnostic Pathology, 2013

DOI 10.1186/1746-1596-8-151 PMID 24044375 14 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Association between human papillomavirus and endometrial adenocarcinoma

Medical Oncology, 2013

DOI 10.1007/s12032-013-0597-5 PMID 23797769 10 Zitationen (Europe PMC) Quelle: OpenAlex